Antibiotice Ia (ATB) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Antibiotice Ia stock RON 1.47, price RON 1.86, that is 21.1% below the price, quality 39 out of 100. Rating: overvalued. Calculated from audited financials with 16 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.
How to read this chart
60‑month range 0.4689 RON – 3.36 RON · fair‑value band 1.03 RON – 1.91 RON · the 1.86 RON price screens above the 1.47 RON fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.
Follow Antibiotice Ia in your weekly email
Every Wednesday you see whether Antibiotice Ia is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Antibiotice S.A. produces and sells medicinal products in Romania and internationally.
Show moreShow less
The company provides generic prescription medicines comprising anti-infectives, including drugs for the treatment of tuberculosis, as well as cardiovascular drugs, digestive tract and metabolism class, preparations for the treatment of gynecological diseases, and dermatological and central nervous system preparations; generic non-prescription medicines, including food supplements, cosmetics, and medical devices; active substances; biofertilizers; biocides for disinfecting surfaces and hands; and veterinary medicines.
Its products are available in the form of sterile injectable powders, capsules, tablets, ointments, gels, creams, pessaries, and suppositories. It offers active pharmaceutical ingredients. The company exports its products to approximately 70 countries.
Antibiotice S.A. was founded in 1955 and is headquartered in Iasi, Romania.
Stock analysis
Antibiotice Ia (ATB) currently trades at 1.86 RON, while our model-based Fair Value estimate is 1.47 RON, 21% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 1.51 RON per share, and 3 of the 16 models we run sit above the 1.86 RON price.
Bear case: the Dividend Discount group reads lowest at 0.2350 RON, and 13 of the 16 models stay below the price. Data coverage for this calculation is low.
Scenario range: 1.03 RON (bear) to 1.91 RON (bull), the price of 1.86 RON sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 39/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Antibiotice Ia reported revenue of 645M RON in FY2025 versus 366M RON in FY2021, a compound +15.2%/yr. Reported net income was 51.8M RON in FY2025, compounding +14.7%/yr from FY2021.
Key figures
Market cap 1.3B RON (≈ $262M) Micro · P/E ratio 186.2 · P/S ratio 2.03 · EPS (TTM) 0.0100 RON · Dividend yield 1.9% · Net margin 1.3% · Return on equity 0.9% · Return on assets (EBIT) 6.5% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 31 out of 100 (low confidence).
What moves the price
The share trades about 28% below its 52-week high and 5% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −21%, ATB screens cheaper than that median.
Fair Value models
Bear1.03 RONFair Value 1.47 RONBull1.91 RON
Price 1.86 RON · Downside -21.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.45/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−4.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.6%
Start year 2020 (pandemic)
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+14.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year+12.9%
Dividend (yield on the price)1.9%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.13% → 10%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks
Beats the industry median on 3/14 measures
Overall it trails its industry peers.
Valuation
Quality Score39 · Bottom 25%
Fair Value upside−21.1% · Below median
Profitability
Return on equity (12 months)0.9% · Below median
Return on assets3.7% · Below median
Net margin (12 months)1.3% · Below median
Operating margin (12 months)10.4% · Below median
Growth and dividend
Revenue growth (quarter YoY)−4.7% · Below median
Dividend yield (12 months)1.9% · Above median
Balance sheet
Debt / equity0.15× · Above median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Antibiotice Ia Fair Value". https://www.fairvalue-calculator.com/stock/ATB
Frequently asked questions
Is Antibiotice Ia (ATB) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of 1.47 RON versus a price of 1.86 RON, about 21% lower (overvalued).
What is the fair value of ATB?
Our model-based fair value for Antibiotice Ia is 1.47 RON (as of Nov 6, 2026), built from audited fundamentals. The current price: 1.86 RON.
What is the quality score of ATB?
Antibiotice Ia has a Quality Score of 39/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Antibiotice Ia (ATB)?
Our model-based price target is the fair value of 1.47 RON (as of Nov 6, 2026) from 16 valuation models. Cautious scenario 1.03 RON, optimistic scenario 1.91 RON. It is a calculation from audited fundamentals, not an analyst target.
What is the Antibiotice Ia stock forecast for 2026?
Our models put fair value at 1.47 RON, about 21% lower versus a price of 1.86 RON (overvalued). Cautious scenario 1.03 RON, optimistic scenario 1.91 RON. The calculation is refreshed regularly with new filings.
What is the revenue of Antibiotice Ia (ATB)?
Antibiotice Ia reported trailing-twelve-month revenue of about 617M RON (latest available figure, as of Nov 6, 2026).
Does Antibiotice Ia pay a dividend?
Antibiotice Ia currently shows a dividend yield of 1.93% relative to its recent price (as of Nov 6, 2026).
How much is the dividend of Antibiotice Ia (ATB) and when is the ex-dividend date?
Antibiotice Ia pays a dividend of 0.036 RON per share a year, a dividend yield of 1.9%. The last ex-dividend date was Oct 15, 2026. A dividend has been paid every year since at least 2012. Our assessment: Pays more than it earns. The company pays out more in dividends than it earns, and free cash flow clearly does not cover the dividend either. It may need to be cut unless profits recover.
What is the intrinsic value of Antibiotice Ia (ATB)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Antibiotice Ia it is 1.47 RON per share (as of Nov 6, 2026), against a price of 1.86 RON. It is the blended result of 16 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Antibiotice Ia stock overvalued or undervalued in 2026?
As of Nov 6, 2026, ATB trades above its calculated fair value: price 1.86 RON, fair value 1.47 RON, a gap of about −21% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ATB?
No. The price is what the market pays today (1.86 RON); the fair value is what the company's own numbers justify (1.47 RON). For Antibiotice Ia the two are 0.3920 RON per share apart. That gap is exactly why we show both numbers side by side.
How much is Antibiotice Ia worth?
The market values Antibiotice Ia at about 1.3B RON (market capitalisation, as of Nov 6, 2026). Per share that is 1.86 RON; our models calculate a fair value of 1.47 RON per share.
What do the bullish and bearish scenarios say about ATB?
Our models span a range for Antibiotice Ia: cautious scenario 1.03 RON, base 1.47 RON, optimistic 1.91 RON per share (as of Nov 6, 2026, price 1.86 RON). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ATB?
Antibiotice Ia trades at a price-to-earnings ratio of 186.2 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 1.47 RON is built from several models across several years. Median P/E at fiscal year-end, 6 fiscal years (2020 to 2025), reported earnings: 12.7. Other multiples: PEG 3.9, P/B 1.3, P/S 2.0, EV/EBITDA 16.5.
What is the PEG ratio of ATB?
The PEG ratio of Antibiotice Ia is 3.89 (P/E divided by earnings growth, as of Nov 6, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Antibiotice Ia (ATB)?
Balance-sheet figures for Antibiotice Ia (as of Nov 6, 2026): return on equity 0.9%, debt of 0.15 per unit of equity. They feed the Quality Score of 39/100, which measures business quality independently of the share price.
How far is ATB from its 52-week high?
Antibiotice Ia trades at 1.86 RON, about 28% below its 52-week high of 2.58 RON and 5% above the low of 1.77 RON (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 1.47 RON is for.
Which stocks are comparable to Antibiotice Ia?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Antibiotice Ia stock attractive at the current price?
The data as of Nov 6, 2026: price 1.86 RON, calculated fair value 1.47 RON (−21%), Quality Score 39/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ATB calculated?
We run Antibiotice Ia through 16 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 1.47 RON builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Antibiotice Ia itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Antibiotice Ia (ATB)?
The closing price on Nov 6, 2026 was 1.86 RON. Our model-based fair value is 1.47 RON, about 21% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Antibiotice Ia right now?
Weak quality (39/100) and above fair value at the same time, the margin of safety is missing on both counts. A fairly wide model range (1.03 RON to 1.91 RON) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Antibiotice Ia
How large is the market capitalisation of Antibiotice Ia (ATB)?
The market capitalisation of Antibiotice Ia is 1.3B RON (≈ $262M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Antibiotice Ia (ATB)?
The price-to-sales ratio of Antibiotice Ia is 2.03 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Antibiotice Ia (ATB)?
Earnings per share at Antibiotice Ia are 0.0100 RON (price ÷ EPS = P/E 186.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Antibiotice Ia (ATB)?
The dividend yield of Antibiotice Ia is 1.9%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Antibiotice Ia (ATB)?
The net margin of Antibiotice Ia is 1.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Antibiotice Ia (ATB)?
The return on equity (ROE) of Antibiotice Ia is 0.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Antibiotice Ia (ATB)?
On an EBIT basis the return on assets of Antibiotice Ia is 6.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Antibiotice Ia (ATB)?
The operating margin of Antibiotice Ia is 10.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Antibiotice Ia (ATB)?
Revenue at Antibiotice Ia is growing −4.7% versus a year earlier (3y avg +10.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Antibiotice Ia (ATB)?
Earnings per share at Antibiotice Ia are growing −88.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Antibiotice Ia (ATB) generate?
The free cash flow of Antibiotice Ia is −70.2M RON (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Antibiotice Ia (ATB) carry?
The net debt of Antibiotice Ia is 224M RON (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Antibiotice Ia in the live analysis
One click puts Antibiotice Ia on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 6, 2026